Lexington, United States
Dicerna Pharmaceuticals, Inc., a wholly owned subsidiary of Novo Nordisk, is at the forefront of RNAi (ribonucleic acid interference) technology. Founded in 2007, the company leverages its proprietary GalXC™ and GalXC-Plus™ technologies to develop therapies that silence specific disease-causing genes. This innovative approach positions Dicerna as a key player in addressing complex medical conditions often resistant to traditional treatments.
The company's scientific team, rich with expertise in biology, chemistry, and clinical science, leads the charge in exploring RNAi applications beyond liver-targeted therapies to include multiple therapeutic areas. With over 20 active programs in rare, cardiometabolic, viral, chronic liver, and neurodegenerative diseases, Dicerna Pharmaceuticals is well-positioned for impactful innovation.
Through strategic collaborations with leading pharmaceutical firms, Dicerna continues to bolster its pipeline, reinforcing its role as an innovator in the biotech landscape.
